Miller Anestesia

Fisiología y anestesia

197. Hughes JR: Clonidine, depression, and smoking ces-

sation. JAMA 259:2901, 1988.

198. Metz SA, Halter JB, Robertson RP: Induction of

defective insulin secretion and impaired glucose

tolerance by clonidine.Selective stimulation of meta-

bolic

-adrenergic pathways. Diabetes 27:554, 1978.

199. Gentili M, Mamelle JC, Le Foll G: Combination of

low-dose bupivacaine and clonidine for unilateral

spinal anesthesia in arthroscopic knee surgery. Reg

Anesth 20:169, 1995.

200. Kapral S, Kocek S, Krafft P, et al: Intrathecal cloni-

dine delays motor onset of bupivacaine [abstract].

Anesthesiology 81:A935, 1994.

201. Venn R, Hell J, Grounds R: Respiratory effects of

dexmedetomidine in the surgical patient requiring

intensive care. Crit Care 4:302, 2000.

202. Bekker A, Sturaitis M: Dexmedetomidine for neu-

rological surgery. Neurosurgery 57(Suppl):1, 2005.

203. Wahlander S, Frumento R,Wagener G, et al: A pros-

pective, double-blind, randomized, placebo-contro-

lled study of dexmedetomidine as an adjunct to

epidural analgesia after thoracic surgery. J Cardio-

thorac Vasc Anesth 19:630, 2005.

204. Opie L, Pode-Wilson P: Beta-blocking agents.

Opie LH, Gersh B (eds): Drugs for the Heart, 6th ed.

Philadelphia, Elsevier Saunders, 2005.

205. Unverferth DV, Blanford M, Kates RE, et al: Tole-

rance to dobutamine after a 72 hour continuous

infusion. Am J Med 69:262, 1980.

206. Leier CV, Huss P, Lewis RP, Unverferth DV: Drug-

induced conditioning in congestive heart failure.

Circulation 65:1382, 1982.

207. Krell MJ,Kline EM,Bates ER,et al:Intermittent,ambu-

latory dobutamine infusions in patients with severe

congestive heart failure. Am Heart J 112:787, 1986.

208. Spitzer W, Suissa S, Ernst P, et al: The use of

-ago-

nists and the risk of death and near death from

asthma. N Engl J Med 326:501, 1992.

209. Robin E, McCauley R: Sudden cardiac death in

bronchial asthma, and inhaled with

-adrenergic

agonists. Chest 101:1699, 1992.

210. Ziment I: Infrequent cardiac deaths occur in bron-

chial asthma. Chest 101:1703, 1992.

211. Yaju Y, Nakayama T: Effectiveness and safety of rito-

drine hydrochloride for the treatment of preterm

labour: A systematic review. Pharmacoepidemiol

Drug Saf 15:813, 2006.

212. Westfall T,Westfall D:Adrenergic agonists and anta-

gonists.

Brunton L, Lazo J, Parker K (eds):

Goodman and Gilman’s The Pharmacological Basis

of Therapeutics, 11th ed. New York, McGraw-Hill,

2006, p 268.

213. Shojania KG, Duncan BW, McDonald KM, et al:

Making health care safer: A critical analysis of

patient safety practices. Evidence report/technology

assessment No. 43 (Prepared by the University of

California at San Francisco–Stanford University

Evidence-Based Practice Center under Contract No.

290-97-0013), AHRQ Publication No. 01-E058.

Rockville, MD,Agency for Healthcare Research and

Quality, July 2001.

214. Stone JG, Foex P, Sear JW, et al: Myocardial ischemia

in untreated hypertensive patients: Effect of a single

small oral dose of a beta-adrenergic blocking agent.

Anesthesiology 68:495, 1988.

215. Mangano DT, Layug EL, Wallace A, et al: Effect of

atenolol on mortality and cardiovascular morbidity

after noncardiac surgery. Multicenter Study of

Perioperative Ischemia Research Group. N Engl J

Med 335:1713, 1996.

216. Poldermans D, Boersma E, Bax JJ, et al: The effect of

bisoprolol on perioperative mortality and myocar-

dial infarction in high-risk patients undergoing

vascular surgery. Dutch Echocardiographic Cardiac

Risk Evaluation Applying Stress Echocardiography

Study Group. N Engl J Med 341:1789, 1999.

217. Raby KE, Brull SJ, Timimi F, et al: The effect of heart

rate control on myocardial ischemia among high-

risk patients after vascular surgery. Anesth Analg

88:477, 1999.

218. Urban MK, Markowitz SM, Gordon MA, et al:

Postoperative prophylactic administration of beta-

adrenergic blockers in patients at risk for myocar-

dial ischemia. Anesth Analg 90:1257, 2000.

219. Stevenson LW: Beta-blockers for stable heart failure.

N Engl J Med 346:1346, 2002.

220. Salpeter SS, Ormiston T, Salpeter E, et al: Cardiose-

lective beta-blockers for chronic obstructive pulmo-

nary disease. Cochrane Database Syst Rev 2:

CD003566, 2002.

221. MERIT-HF Study Group: Effect of metoprolol CR/

XL in chronic heart failure: Metoprolol CR/XL Ran-

domised Intervention Trial in Congestive Heart

Failure (MERIT-HF). Lancet 3532001, 1999.

222. CIBIS-II Investigators and

Committees:The

Cardiac

Insufficiency Bisoprolol Study II (CIBIS-II): A ran-

domised trial. Lancet 353:9, 1999.

223. Furberg C: Secondary prevention trials after myo-

cardial infarction. Am J Cardiol 60:28A, 1987.

224. Rango R, Langlois S: Comparison of withdrawal

phenomena after propranolol, metroprolol, and pin-

dolol. Am Heart J 104:437, 1982.

225. Henry J, Cassidy S: Membrane stabilizing activity: A

major cause of fatal poisoning. Lancet 1:1414, 1986.

226. London MJ: Con: Beta-blockers are indicated for all

adults at increased risk undergoing noncardiac

surgery. Anesth Analg 104:11, 2007.

227. Fleisher L, Beckman JA, Brown KA, et al: for the

ACC/AHA Task Force on Practice Guidelines:

ACC/AHA 2006 guideline update on perioperative

cardiovascular evaluation for noncardiac surgery:

Focused update on perioperative beta-blocker the-

rapy—a report of the American College of Cardio-

logy/American Heart Association Task Force on

Practice Guidelines (Writing Committee to Update

the 2002 Guidelines on Perioperative Cardiovascu-

lar Evaluation for Noncardiac Surgery). Anesth

Analg 104:15, 2007.

228. The POBBLE study (POBBLE Trial Investigators):

Perioperative

-blockade (POBBLE) for patients

undergoing infrarenal vascular surgery: Results of a

randomized double-blind controlled trial. J Vasc

Surg 41602, 2005.

229. Juul AB,Wetterslev J, Gluud C, et al. for the DIPOM

Trial Group. Effect of perioperative

blockade in

patients with diabetes undergoing major non-car-

diac

surgry:Randomized

placebo controlled blinded

multicentre trial. BMJ 332:1482, 2006.

230. Lindenauer PK, Pekow P, Wang K, et al: Periope-

rative beta-blocker therapy and mortality after

major noncardiac surgery. N Engl J Med 353:349,

2005.

231. DeBruijn N, Reves JG, Croughnell N, Knopes K:

Comparison of hemodynamic responses to isopro-

terenol infusion and surgical stress in patients given

cardioselective and noncardioselective

-adrenergic

antagonists. Anesth Analg 66:637, 1987.

232. Olsson G, Rehnqvist N, Sjogren A, et al: Long-term

treatment with metoprolol after myocardial infarc-

tion: Effect on 3 year mortality and morbidity. J Am

Coll Cardiol 5:1428, 1985.

233. Yusuf S: Interventions that potentially limit myocar-

dial infarct size: Overview of clinical trials. Am J

Cardiol 60:11A, 1987.

234. ISIS-1 (First International Study of Infarct Survival)

Collaborative Group: Randomised trial of intrave-

nous atenolol among 16,027 cases of suspected acute

myocardial infarction: ISIS-1. Lancet 157, 1986.

235. Yusuf S, Peto R, Lewis J, et al: Beta blockade during

and after myocardial infarction: An overview of the

randomized trials. Prog Cardiovasc Dis 27:335,

1985.

236. The TIMI Study Group: Comparison of invasive and

conservative strategies after treatment with intrave-

nous tissue plasminogen activator in acute myocar-

dial infarction. N Engl J Med 320618, 1989.

237. Ryden L, Ariniego R, Arnman K, et al: A double-

blind trial of metoprolol in acute myocardial infarc-

tion. Effects on ventricular tachyarrhythmias. N

Engl J Med 308:614, 1983.

238. Bristow MR, Gilbert EM, Abraham WT, et al: Car-

vedilol produces dose-related improvements in left

ventricular function and survival in subjects with

chronic heart failure. MOCHA Investigators. Circu-

lation 94:2807, 1996.

239. Packer M, Colucci WS, Sackner-Bernstein JD, et al:

Double-blind, placebo-controlled study of the

effects of carvedilol in patients with moderate to

severe heart failure. The PRECISE Trial. Prospective

Randomized Evaluation of Carvedilol on Symptoms

and Exercise. Circulation 94:2793, 1996.

240. Eichhorn EJ, Bristow MR: Medical therapy can

improve the biological properties of the chronically

failing heart. A new era in the treatment of heart

failure. Circulation 94:2285, 1996.

241. Communal C, Singh K, Sawyer D, et al: Opposing

effects of

- and

-adrenergic receptors on cardiac

myocyte apoptosis: Role of a pertussis toxin–sensi-

tive G protein. Circulation 100:2210, 1999.

242. Lowes B, Gilbert E, Abraham W, et al: Myocardial

gene expression in dilated cardiomyopathy treated

with beta-blocking agents. N Engl J Med 346:1357,

2002.

243. Eichhorn EJ, Bristow MR: Practical guidelines for

initiation of beta-adrenergic blockade in patients

with chronic heart failure. Am J Cardiol 79:794,

1997.

244. Bristow MR:

-Adrenergic receptor blockade in

chronic heart failure. Circulation 101:558, 2000.

245. FrishmanW: Pindolol: A new

-adrenoceptor anta-

gonist with partial agonist activity. N Engl J Med

308:940, 1983.

246. Van den Meiracker AH, Man in’t Veld AJ, Ritsema

van Eck HJ,et al: Hemodynamic and hormonal adap-

tations to

-adrenoceptor blockade.A 24-hour study

of acebutolol, atenolol, pindolol, and propranolol in

hypertensive patients. Circulation 78:957, 1988.

247. Man in’t Veld AJ, Van den Meiracker AH, Schale-

kamp MA: Do beta-blockers really increase peri-

pheral vascular resistance? Review of the literature

and new observations under basal conditions. Am J

Hypertens 1:91, 1988.

248. Shand D: Propanolol. N Engl J Med 293:280, 1975.

249. Platia E, Fitzpatrick P, Wallis D, et al: Esmolol vs

verapamil for the treatment of recent-onset atrial

afibrillation/flutter. J Am Coll Cardiol 11:170A,

1988.

250. Waldo AL, Camm AJ, deRuyter H, et al: Effect of

d-sotalol on mortality in patients with left ventricu-

lar dysfunction after recent and remote myocardial

infarction. Lancet 348:7, 1996.

251. Doggrell SA, Brown L: d-Sotalol: Death by the

SWORD or deserving of further consideration for

clinical use? Expert Opin Investig Drugs 9:1625,

2000.

252. DeSanctis RW, Doroghazi RM,AustenWG, Buckley

MJ: Aortic dissection. N Engl J Med 317:1060,

1987.

253. Grubb BP, Sirio C, Zelis R: Intravenous labetalol in

acute aortic dissection. JAMA 258:78, 1987.

254. WiersingaWM, Touber JL: The influence of

-adre-

nergic blocking agents on plasma thyroxine and

triiodothyronine. J Clin Endocrinol Metab 45:293,

1977.

255. Psaty B, Koepsell T,Wagner E, et al: The relative risk

of incident coronary heart disease associated with

recently stopping the use of

-blockers. JAMA

263:1653, 1990.